Elaine Ullian Sells 18,236 Shares of Hologic Inc. (HOLX) Stock
Hologic Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 18,236 shares of the business’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $39.88, for a total transaction of $727,251.68. Following the sale, the director now owns 42,898 shares of the company’s stock, valued at $1,710,772.24. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of Hologic Inc. (NASDAQ:HOLX) traded up 0.31% on Wednesday, hitting $38.81. 1,368,877 shares of the company were exchanged. The stock has a market capitalization of $10.77 billion, a PE ratio of 42.79 and a beta of 1.00. Hologic Inc. has a 52-week low of $31.84 and a 52-week high of $41.66. The firm’s 50-day moving average is $38.49 and its 200-day moving average is $36.32.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.03. The business earned $717.40 million during the quarter, compared to analysts’ expectations of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.43 earnings per share. Equities research analysts predict that Hologic Inc. will post $1.94 earnings per share for the current year.
HOLX has been the subject of several analyst reports. Barclays PLC restated a “hold” rating and issued a $42.00 price objective on shares of Hologic in a research note on Sunday, July 10th. Zacks Investment Research upgraded Hologic from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research note on Wednesday, September 28th. Bank of America Corp. restated a “buy” rating on shares of Hologic in a research note on Wednesday, June 22nd. Leerink Swann restated an “outperform” rating and issued a $46.00 price objective on shares of Hologic in a research note on Monday, October 3rd. Finally, Jefferies Group restated a “buy” rating and issued a $42.00 price objective on shares of Hologic in a research note on Tuesday, June 21st. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Hologic presently has an average rating of “Buy” and a consensus price target of $42.71.
Several hedge funds have recently added to or reduced their stakes in HOLX. Glenmede Trust Co. NA boosted its stake in Hologic by 259.8% in the first quarter. Glenmede Trust Co. NA now owns 18,710 shares of the company’s stock worth $644,000 after buying an additional 13,510 shares in the last quarter. BlackRock Japan Co. Ltd boosted its stake in Hologic by 3.1% in the first quarter. BlackRock Japan Co. Ltd now owns 313,303 shares of the company’s stock worth $10,809,000 after buying an additional 9,312 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new stake in Hologic during the first quarter worth approximately $1,270,000. State Street Corp boosted its stake in Hologic by 26.4% in the first quarter. State Street Corp now owns 10,295,836 shares of the company’s stock worth $355,210,000 after buying an additional 2,150,544 shares in the last quarter. Finally, UBS Group AG boosted its stake in Hologic by 5.8% in the first quarter. UBS Group AG now owns 794,751 shares of the company’s stock worth $27,419,000 after buying an additional 43,652 shares in the last quarter. 94.51% of the stock is owned by institutional investors and hedge funds.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.